Skip to main
DTIL

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences is in a strong position for long-term growth, thanks to its innovative ARCUS platform which allows for sophisticated gene editing and has the potential to treat a variety of genetic diseases. The company's gene editing therapy for Duchenne muscular dystrophy (DMD) not only differentiates it from competitors, but also has the potential to be a game-changing treatment option for patients. Despite potential challenges in the administration of their hepatitis B therapy, Precision BioSciences's strong pipeline and promising trial results make it a company to watch in the gene editing space.

Bears say

Precision BioSciences is facing challenges in its gene editing therapies, as evidenced by the multiple doses needed to achieve cccDNA target engagement in the HBV viral genome elimination program, along with significant safety concerns including Grade 3 hypotension and serious adverse events. Additionally, the low success rate in the PBGENE-DMD functional dystrophin gene restoration program and potential manufacturing issues raise questions about the long-term viability and profitability of the company.

Precision Biosciences (DTIL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Precision Biosciences (DTIL) has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.